Fresh analysis reveals that patients who stop using new GLP-1 drugs like Mounjaro or Wegovy may regain shed pounds far faster than those who end conventional diet and exercise plans.
Published data in a leading medical journal shows that while obese individuals frequently drop substantial amounts of their body weight while on the medication, the mass comes back at an estimated rate of nearly a kilo each month after stopping.
"People buying these treatments should be informed of the risk of rapid rebound weight gain when the therapy concludes," stated researcher Dr. Susan Jebb.
Such speed of regain implies a return to starting mass within about a year and a half.
Comparing Approaches
The analysis, which looked at dozens of trials involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with conventional dieting.
Researchers note that people who shed pounds through lifestyle changes alone typically see a more gradual creep back—perhaps 0.1 kg a month—after stopping.
Explaining the Quick Regain
Doctors propose the way of the jabs accounts for the accelerated weight return.
These medications copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production may cause the body to generate a reduced amount of its endogenous hormone, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication leads to hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Disease?
The NHS suggest the injections for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians contend that, considering the high risk of weight regain, the treatment might need to be life-long.
This view is reinforced by pharmaceutical companies, who say that the findings "highlight the long-term character of excess weight," akin to managing conditions like high blood pressure.
User Testimonies
People who have stopped the jabs report a sudden return of cravings.
"I experienced a switch activating and you're instantly extremely hungry," described a patient.
This difficulty is compounded if users have not adopted sustainable dietary or behavioural modifications during therapy.
Widespread Use
Survey data suggest that millions of adults in the UK have tried these injections in the past year, with demand remaining high.
- Adoption is more common among females than males.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than public health services.
Ultimately, experts stress that while these medications are potent tools for shedding pounds, they are not a permanent fix and maintained weight loss relies on combined behavioural support.
